Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com
Dallas, TX (PRWEB) March 04, 2015 -- The report “Vasculitis – Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Vasculitis. Vasculitis is a disease that features tenderness of the blood vessels. The actual cause of vasculitis diseases is not known. Vasculitis can affect any body system and can have a wide range of symptoms. Symptoms can include fever, weight loss, tiredness, aches, pains, night sweats, rash and loss of a pulse in a limb. Vasculitis is treatable, but it is not curable. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/vasculitis-pipeline-review-h1-2015-market-report.html .
The report also reviews key players involved in the therapeutic development for vasculitis and special features on late-stage and discontinued projects. Companies discussed in this Vasculitis – Pipeline Review, H1 2015 report include AnGes MG, Inc., Anthera Pharmaceuticals‚ Inc., Aprogen, Inc., ChemoCentryx, Inc., Clearside BioMedical, Inc., Epirus Biopharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Hemostemix Ltd, Hospira, Inc., K-Stemcell Co., Ltd., Panacea Biotec Limited, Pluristem Therapeutics Inc., Sandoz Inc. and XOMA Corporation.
Drugs profiles discussed in this report include ACP-01, belimumab, beperminogene perplasmid, blisibimod, CCX-168, gevokizumab, rituximab biosimilar, Stem Cell Therapy for Cardiovascular Diseases, tocilizumab, triamcinolone acetonide and Vascostem.
Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=308861 . (This is a premium report priced at US$2000 for a single user License.)
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
“Featured News & Press Releases cover by this report include”: Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis; Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA; Apr 03, 2013: GlaxoSmithKline Starts Phase III Study Of Benlysta In Patients With Vasculitis; Jan 10, 2013: Clearside Biomedical Announces Plans For Clinical Testing Of CLS1001 Suprachoroidal Injectable Suspension For Treatment Of Some Eye Diseases; Aug 17, 2012: Anges Announces Publication Of Long-Term Phase I/II Trial Data Of Collategene In Medical Journal; Aug 16, 2012: Pluristem Receives Approval From Indian Ministry Of Health For Use Of PLX Cells In Phase II Trial For Treatment Of Buerger's Disease; May 26, 2012: ChemoCentryx Presents Data on CCX168 At 49th European Renal Association-European Dialysis And Transplant Association Congress; Oct 17, 2011: ChemoCentryx Initiates Phase II Clinical Trial For CCX168 In Vasculitis; Mar 24, 2011: AnGes Publishes Results Of Collategene Study In International Angiology.
Table of content
List of Table
Number of Products under Development for Vasculitis, H1 2015
Number of Products under Development for Vasculitis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Vasculitis - Pipeline by AnGes MG, Inc., H1 2015
Vasculitis - Pipeline by Anthera Pharmaceuticals Inc., H1 2015
Vasculitis - Pipeline by Aprogen, Inc., H1 2015
Vasculitis - Pipeline by ChemoCentryx, Inc., H1 2015
Vasculitis - Pipeline by Clearside BioMedical, Inc., H1 2015
Vasculitis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
Vasculitis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Vasculitis - Pipeline by GlaxoSmithKline plc, H1 2015
Vasculitis - Pipeline by Hemostemix Ltd, H1 2015
Vasculitis - Pipeline by Hospira, Inc., H1 2015
Vasculitis - Pipeline by K-Stemcell Co., Ltd., H1 2015
Vasculitis - Pipeline by Panacea Biotec Limited, H1 2015
Vasculitis - Pipeline by Pluristem Therapeutics Inc., H1 2015
Vasculitis - Pipeline by Sandoz Inc., H1 2015
Vasculitis - Pipeline by XOMA Corporation, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Vasculitis Therapeutics - Recent Pipeline Updates, H1 2015
Vasculitis - Dormant Projects, H1 2015
Explore more reports on Inflammation Drugs at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/inflammation-drugs .
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.
Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article